Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress EncouragingZacks Investment Research • 05/09/25
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory DiseasesGlobeNewsWire • 05/09/25
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/09/25
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care ConferenceGlobeNewsWire • 05/07/25
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 DegraderGlobeNewsWire • 04/22/25
Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?Zacks Investment Research • 04/10/25
Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?Zacks Investment Research • 01/15/25
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology ProgramsGlobeNewsWire • 01/14/25
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14GlobeNewsWire • 01/07/25
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 10/31/24
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 10/31/24
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/24/24
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory DiseasesGlobeNewsWire • 10/24/24
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31GlobeNewsWire • 10/23/24
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 SymposiumGlobeNewsWire • 10/23/24